A multi-center study to evaluate the efficacy and safety of cetuximab in patients with bladder cancer

Trial Profile

A multi-center study to evaluate the efficacy and safety of cetuximab in patients with bladder cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2016 New trial record
    • 25 Nov 2008 The National Comprehensive Cancer Network (NCCN) was awarded a $US1.5 million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research of cetuximab in patients with bladder cancer, according to a NCCN media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top